Key clinical point: Sintilimab plus IBI305 (a bevacizumab biosimilar) exhibits a promising efficacy and safety profile in patients with advanced hepatocellular carcinoma (HCC).
Major finding: After a median follow-up of 17.8 months, the overall response rate was 34.0% (95% CI 20.0%-48.0%) and the median progression-free survival and overall survival were 10.5 months (95% CI 8.3-12.7 months) and 20.2 months (95% CI 16.1-24.3 months), respectively. The grade 3-5 adverse event rate was 20.0%.
Study details: Findings are from a single-center phase 1b clinical trial that included 50 patients with advanced HCC who received sintilimab plus IBI305 every 3 weeks.
Disclosures: This study was partly supported by the Non-profit Central Research Institution Fund of the Chinese Academy of Medical Sciences. The authors declared no conflicts of interest.
Source: Zhang W et al. Serum concentration of CD137 and tumor infiltration by M1 macrophages predict the response to sintilimab plus bevacizumab biosimilar in advanced hepatocellular carcinoma patients. Clin Cancer Res. 2022;28(16):3499-3508 (Aug 15). Doi: 10.1158/1078-0432.CCR-21-3972